{"transactions":[{"id":689591,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-08-12T12:18:46.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":177978,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The principal amount of the convertible promissory note (the \"Note\"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The principal amount of the convertible promissory note (the \"Note\"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The principal amount of the convertible promissory note (the \"Note\"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The principal amount of the convertible promissory note (the \"Note\"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":177978},"source":{"system":"sec-edgar","filing":"0001193125-26-345826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526345826/ownership.xml","form_type":"4"}},{"id":689590,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-12T12:18:46.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":494800,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the \"IPO\") without payment of consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the \"IPO\") without payment of consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the \"IPO\") without payment of consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the \"IPO\") without payment of consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":494800},"source":{"system":"sec-edgar","filing":"0001193125-26-345826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526345826/ownership.xml","form_type":"4"}},{"id":689589,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T12:18:46.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":177978,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The principal amount of the convertible promissory note (the \"Note\"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":672788,"source":{"system":"sec-edgar","filing":"0001193125-26-345826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526345826/ownership.xml","form_type":"4"}},{"id":689588,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T12:18:46.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":494800,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the \"IPO\") without payment of consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":494800,"source":{"system":"sec-edgar","filing":"0001193125-26-345826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526345826/ownership.xml","form_type":"4"}},{"id":693378,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-08-07T19:45:54.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":782855,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C preferred stock (the \"Preferred Stock\") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the \"IPO\") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026."},{"field":"date","element":"transactionDate","label":"F1","text":"The Series C preferred stock (the \"Preferred Stock\") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the \"IPO\") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C preferred stock (the \"Preferred Stock\") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the \"IPO\") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C preferred stock (the \"Preferred Stock\") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the \"IPO\") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C preferred stock (the \"Preferred Stock\") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the \"IPO\") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":782855},"source":{"system":"sec-edgar","filing":"0001193125-26-340173","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526340173/ownership.xml","form_type":"4"}},{"id":693377,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T19:45:54.000Z","date":"2026-08-06","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":17,"value":5100000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase in the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":1082855,"source":{"system":"sec-edgar","filing":"0001193125-26-340173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526340173/ownership.xml","form_type":"4"}},{"id":693376,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T19:45:54.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":782855,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C preferred stock (the \"Preferred Stock\") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the \"IPO\") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries."}],"balance_after":782855,"source":{"system":"sec-edgar","filing":"0001193125-26-340173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526340173/ownership.xml","form_type":"4"}},{"id":2571186,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2021-09-14T13:59:09.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":20515985,"price":38,"value":779607430.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects all of the outstanding Shares not tendered in the Offer and not owned by Sanofi or its wholly-owned subsidiaries prior to the Offer, which may be deemed to have been acquired pursuant to the consummation of the Merger (as defined below). Pursuant to the Merger, Sanofi now beneficially owns all outstanding Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Following the consummation of the Offer, Merger Sub was merged with and into Translate Bio, and Translate Bio survived the Merger as an indirect, wholly-owned subsidiary of Sanofi pursuant to a \"back-end merger\" under Delaware law (the \"Merger\"). Prior to the Merger, Sanofi indirectly held 100 shares of Merger Sub, which represented all of the issued and outstanding capital stock of Merger Sub. At the effective time of the Merger, all of the shares of Merger Sub were converted into 71,983,597 shares of Translate Bio stock."}],"balance_after":75668031,"source":{"system":"sec-edgar","filing":"0000899243-21-035757","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924321035757/doc4.xml","form_type":"4"}},{"id":2571185,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2021-09-14T13:59:09.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":51467612,"price":38,"value":1955769256.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock, par value $0.001 per share (the \"Shares\"), of Translate Bio, Inc. (\"Translate Bio\") acquired by Sanofi and its wholly-owned subsidiaries pursuant to the tender offer effected pursuant to the Agreement and Plan of Merger, dated as of August 2, 2021 (the \"Merger Agreement\"), by and among Sanofi, Vector Merger Sub, Inc., an indirect, wholly owned subsidiary of Sanofi (\"Merger Sub\"), and Translate Bio (such tender offer, the \"Offer\"). Prior to the Offer, Sanofi beneficially owned 3,684,434 Shares (approximately 4.87%)."}],"balance_after":55152046,"source":{"system":"sec-edgar","filing":"0000899243-21-035757","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924321035757/doc4.xml","form_type":"4"}},{"id":2620294,"issuer":{"id":94107,"kind":"organization","name":"Icosavax, Inc.","symbol":"ICVX"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock (par value, $0.0001)","published_at":"2021-08-03T00:34:24.000Z","date":"2021-08-02","kind":"exercise","acquired":false,"shares":354393,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sanofi is the beneficial owner of 3,155,169  Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":85278},"source":{"system":"sec-edgar","filing":"0000899243-21-031120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924321031120/doc4.xml","form_type":"4"}},{"id":2620293,"issuer":{"id":94107,"kind":"organization","name":"Icosavax, Inc.","symbol":"ICVX"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock (par value, $0.0001)","published_at":"2021-08-03T00:34:24.000Z","date":"2021-08-02","kind":"exercise","acquired":false,"shares":12480498,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sanofi is the beneficial owner of 3,155,169  Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3003224},"source":{"system":"sec-edgar","filing":"0000899243-21-031120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924321031120/doc4.xml","form_type":"4"}},{"id":2620292,"issuer":{"id":94107,"kind":"organization","name":"Icosavax, Inc.","symbol":"ICVX"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value, $0.0001)","published_at":"2021-08-03T00:34:24.000Z","date":"2021-08-02","kind":"purchase","acquired":true,"shares":66667,"price":15,"value":1000005.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reporting person acquired additional shares in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sanofi is the beneficial owner of 3,155,169  Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc."}],"balance_after":3155169,"source":{"system":"sec-edgar","filing":"0000899243-21-031120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924321031120/doc4.xml","form_type":"4"}},{"id":2620291,"issuer":{"id":94107,"kind":"organization","name":"Icosavax, Inc.","symbol":"ICVX"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value, $0.0001)","published_at":"2021-08-03T00:34:24.000Z","date":"2021-08-02","kind":"exercise","acquired":true,"shares":3088502,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sanofi is the beneficial owner of 3,155,169  Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc."}],"balance_after":3088502,"source":{"system":"sec-edgar","filing":"0000899243-21-031120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924321031120/doc4.xml","form_type":"4"}},{"id":3074303,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock (par value, $0.0001)","published_at":"2020-07-29T10:06:37.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":3279720,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":438875},"source":{"system":"sec-edgar","filing":"0000899243-20-020587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924320020587/doc4.xml","form_type":"4"}},{"id":3074302,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value $0.0001)","published_at":"2020-07-29T10:06:37.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":81250,"price":16,"value":1300000.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person acquired additional shares in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person acquired additional shares in the Issuer's initial public offering."}],"balance_after":520125,"source":{"system":"sec-edgar","filing":"0000899243-20-020587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924320020587/doc4.xml","form_type":"4"}},{"id":3074301,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value $0.0001)","published_at":"2020-07-29T10:06:37.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":438875,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2020, Series A Convertible Preferred Stock (par value, $0.0001) converted into the Issuer's Common Stock on a 7.473-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of INZY and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of INZY."}],"balance_after":438875,"source":{"system":"sec-edgar","filing":"0000899243-20-020587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924320020587/doc4.xml","form_type":"4"}},{"id":3113995,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-06-11T22:45:33.000Z","date":"2020-06-09","kind":"sale","acquired":false,"shares":120234,"price":597.48,"value":71837410.32,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the \"Sanofi Parties\") and the Issuer, as amended, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Directly owned by Aventisub LLC (\"Aventisub\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of the Reporting Person."}],"balance_after":279766,"source":{"system":"sec-edgar","filing":"0001140361-20-013625","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036120013625/form4.xml","form_type":"4"}},{"id":3131262,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-05-29T20:16:39.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":2399552,"price":509.85,"value":1223411587.2,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents sale in public offering to underwriters by Aventisub LLC (\"Aventisub\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Directly owned by Aventisub, formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of the Reporting Person."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the \"Sanofi Parties\") and the Issuer, as amended, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Directly owned by Aventisub, formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of the Reporting Person."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0001140361-20-012718","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036120012718/form4.xml","form_type":"4"}},{"id":3131261,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-05-29T20:16:39.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":20421899,"price":509.85,"value":10412105205.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents sale in public offering to underwriters (10,615,094 shares) and a sale in private transaction to the Issuer (9,806,805 shares), in each case, by the Reporting Person."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the \"Sanofi Parties\") and the Issuer, as amended, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-20-012718","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036120012718/form4.xml","form_type":"4"}},{"id":3216585,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-03-11T21:00:16.000Z","date":"2020-03-09","kind":"sale","acquired":false,"shares":128914,"price":489.6532,"value":63123152.6248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":20421899,"source":{"system":"sec-edgar","filing":"0001140361-20-005506","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036120005506/form4.xml","form_type":"4"}},{"id":3416693,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-09-12T21:00:44.000Z","date":"2019-09-10","kind":"sale","acquired":false,"shares":172904,"price":281.1491,"value":48611803.9864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":20550813,"source":{"system":"sec-edgar","filing":"0001140361-19-016600","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036119016600/form4.xml","form_type":"4"}},{"id":3457519,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock (par value $0.001)","published_at":"2019-07-23T15:39:19.000Z","date":"2019-07-22","kind":"exercise","acquired":false,"shares":3250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":464285},"source":{"system":"sec-edgar","filing":"0000899243-19-020073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924319020073/doc4.xml","form_type":"4"}},{"id":3457518,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value $0.001)","published_at":"2019-07-23T15:39:19.000Z","date":"2019-07-22","kind":"purchase","acquired":true,"shares":93750,"price":16,"value":1500000.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person acquired additional shares in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person acquired additional shares in the Issuer's initial public offering."}],"balance_after":558035,"source":{"system":"sec-edgar","filing":"0000899243-19-020073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924319020073/doc4.xml","form_type":"4"}},{"id":3457517,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value $0.001)","published_at":"2019-07-23T15:39:19.000Z","date":"2019-07-22","kind":"exercise","acquired":true,"shares":464285,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Through its wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration.  The shares have no expiration date.  As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC."}],"balance_after":464285,"source":{"system":"sec-edgar","filing":"0000899243-19-020073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924319020073/doc4.xml","form_type":"4"}},{"id":3600526,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-03-13T00:19:21.000Z","date":"2019-03-08","kind":"sale","acquired":false,"shares":131115,"price":412.1673,"value":54041315.5395,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among the Reporting Person, sanofi-aventis US LLC, Aventis, sanofi-aventis Amerique du Nord (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":20723717,"source":{"system":"sec-edgar","filing":"0001140361-19-004808","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036119004808/form4.xml","form_type":"4"}},{"id":3654113,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (par value $0.0001)","published_at":"2019-02-15T11:05:21.000Z","date":"2019-02-13","kind":"sale","acquired":false,"shares":4168899,"price":37.66,"value":157000736.34,"ownership":{"direct":false,"nature":"Via wholly-owned subsidiary, Aventis Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 13, 2019, the reporting person sold 4,168,899 shares of MYOK at a price of $37.66 (the \"Transaction\"). As a result of the Transaction, the reporting person no longer owns shares of common stock of MYOK and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of MYOK."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-003822","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924319003822/doc4.xml","form_type":"4"}},{"id":3821421,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-09-10T21:01:49.000Z","date":"2018-09-06","kind":"sale","acquired":false,"shares":104552,"price":406.6804,"value":42519249.1808,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to Amendment No. 13 to Reporting Person's statement on Schedule 13D."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Indirectly owned through (a) sanofi-aventis Amerique du Nord, a direct, wholly-owned subsidiary of Sanofi (\"SAAN\"), and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to the dispositions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,854,832 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23654384,"source":{"system":"sec-edgar","filing":"0001140361-18-038175","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036118038175/form4.xml","form_type":"4"}},{"id":3899198,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-06-11T20:30:52.000Z","date":"2018-06-08","kind":"sale","acquired":false,"shares":121601,"price":309.3057,"value":37611882.4257,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Private sale to the Issuer pursuant to the letter agreement entered into with the Issuer on January 7, 2018 and filed on January 9, 2018 by the Reporting Person as Exhibit 99.4 to the Amendment No. 13 to its statement on Schedule 13D."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Indirectly owned through (a) sanofi-aventis Amerique du Nord, a direct, wholly-owned subsidiary of Sanofi (\"SAAN\"), and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to the dispositions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,959,384 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23758936,"source":{"system":"sec-edgar","filing":"0001140361-18-028055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036118028055/form4.xml","form_type":"4"}},{"id":3915803,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock Par value per share $ 0.0001","published_at":"2018-05-29T20:34:38.000Z","date":"2018-05-25","kind":"purchase","acquired":true,"shares":150000,"price":49,"value":7350000.0,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary Aventis Inc."},"balance_after":4168899,"source":{"system":"sec-edgar","filing":"0000899243-18-014266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924318014266/doc4.xml","form_type":"4"}},{"id":4222955,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":2557,"price":487.0108,"value":1245286.6156,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Purchase prices range from $486.92 to $487.57 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23880537,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222954,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":2681,"price":485.9939,"value":1302949.6459,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Purchase prices range from $485.86 to $486.79 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23877980,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222953,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":5723,"price":485.2798,"value":2777256.2954,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Purchase prices range from $484.86 to $485.85 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23875299,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222952,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":2000,"price":484.21,"value":968420.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Purchase prices range from $483.70 to $484.63 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23869576,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222951,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":4485,"price":482.8734,"value":2165687.199,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Purchase prices range from $482.49 to $483.45 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23867576,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222950,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":1302,"price":481.6284,"value":627080.1768,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Purchase prices range from $481.47 to $482.09 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23863091,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222949,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":21360,"price":480.7489,"value":10268796.504,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Purchase prices range from $480.44 to $481.32 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23861789,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222948,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":28586,"price":479.9313,"value":13719316.1418,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Purchase prices range from $479.43 to $480.39 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23840429,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4222947,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-29T21:00:23.000Z","date":"2017-08-25","kind":"purchase","acquired":true,"shares":3684,"price":479.1912,"value":1765340.3808,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $478.42 to $479.39 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly known as Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,080,985 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23811843,"source":{"system":"sec-edgar","filing":"0001140361-17-033562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033562/form4.xml","form_type":"4"}},{"id":4224946,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":6960,"price":488.574,"value":3400475.04,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"Purchase prices range from $488.04 to $488.82 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23808159,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224945,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":8860,"price":487.5532,"value":4319721.352,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Purchase prices range from $487.02 to $488.01 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23801199,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224944,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":6920,"price":486.6264,"value":3367454.688,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"Purchase prices range from $486.01 to $486.95 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23792339,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224943,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":5724,"price":485.5536,"value":2779308.8064,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Purchase prices range from $485.00 to $485.98 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23785419,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224942,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":8982,"price":484.2671,"value":4349687.0922,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Purchase prices range from $483.93 to $484.74 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23779695,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224941,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":5016,"price":483.3125,"value":2424295.5,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Purchase prices range from $482.91 to $483.90 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23770713,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224940,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":1700,"price":481.9565,"value":819326.05,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Purchase prices range from $481.89 to $482.59 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23765697,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224939,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":17756,"price":481.3267,"value":8546436.8852,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Purchase prices range from $480.82 to $481.80 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23763997,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224938,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":13638,"price":480.3643,"value":6551208.3234,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Purchase prices range from $479.80 to $480.77 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23746241,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224937,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":8273,"price":479.2349,"value":3964710.3277,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Purchase prices range from $478.79 to $479.70 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23732603,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224936,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":3326,"price":478.1171,"value":1590217.4746,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Purchase prices range from $477.79 to $478.76 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23724330,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224935,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":10929,"price":477.4224,"value":5217749.4096,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Purchase prices range from $476.79 to $477.78 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23721004,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224934,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":5103,"price":475.9319,"value":2428680.4857,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Purchase prices range from $475.55 to $476.43 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23710075,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224933,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-24","kind":"purchase","acquired":true,"shares":2633,"price":474.8578,"value":1250300.5874,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Purchase prices range from $474.40 to $475.21 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23704972,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224932,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-23","kind":"purchase","acquired":true,"shares":13037,"price":480.3731,"value":6262624.1047,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Purchase prices range from $479.91 to $480.86 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23702339,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224931,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-23","kind":"purchase","acquired":true,"shares":23872,"price":479.451,"value":11445454.272,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Purchase prices range from $478.89 to $479.87 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23689302,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224930,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-23","kind":"purchase","acquired":true,"shares":12186,"price":478.3422,"value":5829078.0492,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Purchase prices range from $477.81 to $478.80 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23665430,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224929,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-23","kind":"purchase","acquired":true,"shares":9600,"price":477.3484,"value":4582544.64,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Purchase prices range from $476.78 to $477.75 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23653244,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4224928,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-08-25T21:00:18.000Z","date":"2017-08-23","kind":"purchase","acquired":true,"shares":1900,"price":475.9732,"value":904349.08,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $475.51 to $476.50 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventisub LLC (\"Aventis\"), formerly Aventis Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 21,008,607 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23643644,"source":{"system":"sec-edgar","filing":"0001140361-17-033310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117033310/form4.xml","form_type":"4"}},{"id":4232711,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock Par value per share $ 0.0001","published_at":"2017-08-16T11:31:14.000Z","date":"2017-08-14","kind":"purchase","acquired":true,"shares":350000,"price":35.5,"value":12425000.0,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary Aventis Inc."},"balance_after":4018899,"source":{"system":"sec-edgar","filing":"0000899243-17-020410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924317020410/doc4.xml","form_type":"4"}},{"id":4291853,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":4708,"price":484.0367,"value":2278844.7836,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Purchase prices range from $483.57 to $484.50 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23641744,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291852,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":18311,"price":483.0403,"value":8844950.9333,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Purchase prices range from $482.57 to $483.50 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23637036,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291851,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":23490,"price":482.0789,"value":11324033.361,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Purchase prices range from $481.57 to $482.56 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23618725,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291850,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":15197,"price":481.1292,"value":7311720.4524,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Purchase prices range from $480.54 to $481.53 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23595235,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291849,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":12710,"price":480.1698,"value":6102958.158,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Purchase prices range from $479.54 to $480.51 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23580038,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291848,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":6507,"price":478.9431,"value":3116482.7517,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Purchase prices range from $478.53 to $479.48 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23567328,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291847,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":6312,"price":476.1472,"value":3005441.1264,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Purchase prices range from $475.70 to $476.47 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23560821,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291846,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":12020,"price":475.1593,"value":5711414.786,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Purchase prices range from $474.50 to $475.49 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23554509,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291845,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":7068,"price":473.8843,"value":3349414.2324,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Purchase prices range from $473.45 to $474.10 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23542489,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291844,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":5806,"price":473.0711,"value":2746650.8066,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Purchase prices range from $472.45 to $473.33 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23535421,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291843,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":7443,"price":471.8245,"value":3511789.7535,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Purchase prices range from $471.43 to $472.25 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23529615,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291842,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":13544,"price":470.7248,"value":6375496.6912,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Purchase prices range from $470.31 to $470.99 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23522172,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291841,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":2132,"price":469.8097,"value":1001634.2804,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Purchase prices range from $469.19 to $470.04 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23508628,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291840,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":400,"price":468.1,"value":187240.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Purchase prices range from $468.01 to $468.29 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23506496,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4291839,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-06-06T21:00:40.000Z","date":"2017-06-02","kind":"purchase","acquired":true,"shares":402,"price":466.3828,"value":187485.8856,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $465.88 to $466.56 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23506096,"source":{"system":"sec-edgar","filing":"0001140361-17-023988","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117023988/form4.xml","form_type":"4"}},{"id":4298318,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-06-01T23:41:24.000Z","date":"2017-05-31","kind":"purchase","acquired":true,"shares":297501,"price":71.87,"value":21381396.87,"ownership":{"direct":false,"nature":"Via wholly-owned subsidiary, Genzyme Corp."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Purchase of shares in accordance with the terms of the investor agreement between Alnylam and Genzyme (a Sanofi company) dated February 27, 2014."}],"balance_after":10554134,"source":{"system":"sec-edgar","filing":"0000899243-17-015022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924317015022/doc4.xml","form_type":"4"}},{"id":4491458,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":2110,"price":379.5636,"value":800879.196,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Purchase prices range from $379.38 to $379.80 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23505694,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491457,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":9520,"price":378.7635,"value":3605828.52,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"Purchase prices range from $378.37 to $379.36 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23503584,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491456,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":5313,"price":377.8368,"value":2007446.9184,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Purchase prices range from $377.36 to $378.35 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23494064,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491455,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":3851,"price":376.7488,"value":1450859.6288,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"Purchase prices range from $376.36 to $377.34 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23488751,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491454,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":3016,"price":375.8789,"value":1133650.7624,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Purchase prices range from $375.36 to $376.34 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23484900,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491453,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":3830,"price":374.5922,"value":1434688.126,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Purchase prices range from $374.31 to $375.24 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23481884,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491452,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":2784,"price":373.9018,"value":1040942.6112,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Purchase prices range from $373.30 to $374.28 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23478054,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491451,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":2675,"price":372.8741,"value":997438.2175,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Purchase prices range from $372.29 to $373.27 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23475270,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491450,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":1259,"price":371.5346,"value":467762.0614,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Purchase prices range from $371.05 to $372.02 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23472595,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491449,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":900,"price":370.1789,"value":333161.01,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Purchase prices range from $369.87 to $370.59 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23471336,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491448,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":2517,"price":369.3,"value":929528.1,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Purchase prices range from $368.84 to $369.79 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23470436,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491447,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":2336,"price":368.3472,"value":860459.0592,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Purchase prices range from $367.84 to $368.78 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23467919,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491446,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":1986,"price":367.2911,"value":729440.1246,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Purchase prices range from $366.83 to $367.81 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23465583,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491445,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":3979,"price":366.0528,"value":1456524.0912,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Purchase prices range from $365.80 to $366.73 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23463597,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491444,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":19858,"price":365.2018,"value":7252177.3444,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Purchase prices range from $364.80 to $365.79 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23459618,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491443,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":13226,"price":364.3224,"value":4818528.0624,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Purchase prices range from $363.80 to $364.77 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23439760,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491442,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":6546,"price":363.3534,"value":2378511.3564,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Purchase prices range from $362.80 to $363.79 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23426534,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4491441,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2017-01-13T21:15:22.000Z","date":"2017-01-11","kind":"purchase","acquired":true,"shares":1592,"price":362.4664,"value":577046.5088,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares acquired directly by sanofi-aventis Amerique du Nord (\"SAAN\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchase prices range from $361.76 to $362.71 per share, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. (\"Aventis\"), an indirect, wholly-owned subsidiary of SAAN.  After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively.  Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the \"Sanofi Parties\") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors."}],"balance_after":23419988,"source":{"system":"sec-edgar","filing":"0001140361-17-001832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000114036117001832/form4.xml","form_type":"4"}},{"id":4584943,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":2902,"kind":"organization","name":"Sanofi","position":1,"cik":"0001121404","reported_name":"Sanofi","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock Par value per share $ 0.0001","published_at":"2016-10-05T13:00:32.000Z","date":"2016-10-03","kind":"purchase","acquired":true,"shares":450000,"price":15,"value":6750000.0,"ownership":{"direct":false,"nature":"Via wholly owned subsidiary Aventis Inc."},"balance_after":3668899,"source":{"system":"sec-edgar","filing":"0000899243-16-031096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1121404/000089924316031096/doc4.xml","form_type":"4"}}]}